Immuron Ltd (IMRN) News & EventsIMRNImmuron Ltd

Immuron Publishes Travelan Clinical Trial Data

Immuron announced that data from its Phase 2 clinical trial of once-daily oral Travelan has been published in the Nature Journal, Scientific Reports. The clinical study, partially funded by the U.S. Department of Defense, demonstrated that Travelan was safe and well tolerated, with a statistically significant 50% reduction in ETEC challenge-related adverse events versus placebo. Although the study did not meet its primary efficacy endpoints, a lower than anticipated placebo attack rate - 33% versus 70% - materially reduced statistical power. Notwithstanding this limitation, efficacy results consistently trended in favour of Travelan across multiple clinically meaningful endpoints, supporting the potential protective benefit of the once-daily formulation against ETEC-associated disease. Results included a statistically significant 50% reduction in ETEC challenge-related adverse events versus placebo, a 40% reduction in moderate-to-severe diarrhoea, a 50% reduction in severe diarrhoea, a 44% reduction in all diarrhoea, and a 71% reduction in early antibiotic use. More than 80% of subjects in both arms seroconverted by day 15-29, indicating Travelan did not impair natural adaptive immunity to the challenge strain. These observations support the potential for Travelan to enhance gut microbiome resilience during pathogenic challenge and antibiotic exposure, representing an additional mechanism by which the product may contribute to gastrointestinal health. Immuron is advancing Travelan as a next-generation, non-antibiotic oral immunoprophylactic for the prevention of bacterial diarrhoeal disease.

Immuron Signs Exclusive Distribution Agreement for Proibs with Calmino Group AB

Immuron announces that it has executed an exclusive distribution agreement for Proibs in the United States with Calmino group AB. Immuron launched Proibs in Australia during FY26. Flavio Palumbo, Chief Commercial Officer said "Following the rapid growth of Travelan sales in the US, we have developed a commercial growth strategy to bring a portfolio of innovative digestive health products to market. Proibs is a great opportunity to further expand our digestive health portfolio by providing our customers with a proven premium product that delivers improvement in daily life. With Proibs , we are able to provide an innovative and European certified medical device. The product has been on the Swedish pharmacy market for more than a decade. Because it is backed by science and recommended by physicians and dietitians, we can promote Proibs with absolute confidence. We are looking forward to offering a solution that truly improves the livability of the affected people."

Trump Administration Injects $150M into xLight

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.XLIGHT STAKE:The Trump administration has agreed to inject up to $150M into xLight, which makes lasers for EUV machines and has former IntelCEO Pat Gelsinger on its board, for an equity stake, The Wall Street Journal's Amrith Ramkumar and Robbie Whelan. ASMLis currently the only global producer of EUV machines, which can cost hundreds of millions of dollars each.AMICABLE SETTLEMENT:Trump Media and Technologyannounced that Trump Media and United Atlantic Ventures reached an "amicable" settlement of their dispute and all claims by Trump Media against United Atlantic Ventures have been mutually resolved.NEW DOD AWARD:Immuronannounced a new research agreement with the Naval Medical Research Command -NMRC - and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.The Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron.Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the U.S. military. Also, the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. In P2TD study, IMM-124E - the active ingredient in Travelan - was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial.Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among U.S. troops deployed overseas. In the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics.